Hu Chang-chen, Ke Yi-quan, Sun Xin-lin, Jiang Xiao-dan, Xu Ru-xiang, Lv Jun, Wang Yu-sheng, Cai Ying-qian, Qin Ling-sha, Zou Yu-xi
Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, 253 GongYe Road, Guangzhou, 510282, People's Republic of China.
Biotechnol Lett. 2009 Feb;31(2):181-9. doi: 10.1007/s10529-008-9860-9. Epub 2008 Oct 16.
Human mesenchymal stem cells-like cells (hMSCs-like cells) were used as a tumor treatment platform for the systemic delivery of immunotoxin genes. VEGF165-PE38 recombinant immunotoxin served as the model system. hMSCs-like cells were isolated, expanded, and electroporated with the pIRES2-VEGF165PE38-EGFP plasmid. RT-PCR and ELISA were used to confirm the expression of VEGF165-PE38 in the transfected hMSCs-like cells. These cells released 1390 +/- 137 pg VEGF165-PE38/10(4)cells over 48 h into the culture medium and the supernatant was capable of selectively killing human umbilical vein endothelial cells (HUVECs) and increasing apoptosis in these cells. In contrast, RPMI8226 was not inhibited by identical supernatants. Thus, these results lay the foundation for further studies on the potential role of hMSCs-like cells as a targeted therapeutic delivery vehicle for immunotoxins.
人骨髓间充质干细胞样细胞（hMSCs样细胞）被用作免疫毒素基因全身递送的肿瘤治疗平台。VEGF165-PE38重组免疫毒素作为模型系统。分离、扩增hMSCs样细胞，并用pIRES2-VEGF165PE38-EGFP质粒进行电穿孔。采用RT-PCR和ELISA法证实转染的hMSCs样细胞中VEGF165-PE38的表达。这些细胞在48小时内将1390±137 pg VEGF165-PE38/10(4)细胞释放到培养基中，其上清液能够选择性杀伤脐静脉内皮细胞（HUVECs）并增加这些细胞的凋亡。相比之下，RPMI8226不受相同上清液的抑制。因此，这些结果为进一步研究hMSCs样细胞作为免疫毒素靶向治疗递送载体的潜在作用奠定了基础。
